Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Post-Trial Drug Access
Drugs
Locations
Clinical Specialty
781-800 of 847 trials

Felzartamab for Kidney Transplant Recipients with Late Antibody-Mediated Rejection

We are studying whether felzartamab can improve outcomes for kidney transplant recipients facing late antibody-mediated rejection. This trial compares the new treatment to a placebo to assess its effectiveness and safety.

Kidney Transplant Rejection1-2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesNephrology

Alzheimer's Disease: MK-2214 Study

We are testing a new medication, MK-2214, in people with early Alzheimer's disease to see if it may slow the progression of brain changes. The study will also evaluate the safety of this treatment compared to a placebo.

Alzheimer's Disease>2 yearsEfficacy phase (II)>20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementNeurology

Ravulizumab Dosing for PNH Patients

We are studying whether personalized dosing of ravulizumab is more effective than standard dosing for adults with PNH. This trial also looks at patient preferences and treatment costs.

Paroxysmal Nocturnal Hemoglobinuria1-2 yearsMonitoring phase (IV)Post-Trial Drug AccessNo PlaceboStandard MedicinesHematologyInternal Medicine

Major Depressive Disorder: CYB003 Treatment Study

We are studying the effects of a new medication, CYB003, on symptoms of major depressive disorder in adults. This trial compares its effectiveness to a placebo to see if it may help improve mood and quality of life.

Major Depressive Disorder3-6 monthsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemotePsychiatry

Chronic HDV Infection: Tobevibart and Elebsiran Study

We are studying a new combination therapy for people with chronic HDV infection who haven't responded to prior treatment. The goal is to see if this therapy can effectively reduce the virus and improve liver health.

Chronic Hepatitis D Virus Infection>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementHepatologyInfectious Diseases

Metastatic Colorectal Cancer: Cetuximab vs. Bevacizumab

We are studying whether continuing cetuximab treatment helps patients with specific types of metastatic colorectal cancer after their first treatment stops working. This trial compares it to another treatment option to see which is more effective.

Metastatic Colorectal CancerConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesOncology

Low-Grade Upper Tract Urothelial Cancer: UGN-104 Treatment Study

We are studying a new treatment called UGN-104 for patients with low-grade upper tract urothelial cancer. The trial aims to see how well it reduces tumors and its safety compared to existing options.

Low-grade Upper Tract Urothelial Cancer1-2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementOncologyUrology

IgA Nephropathy: Felzartamab Infusions

We are studying the effects of felzartamab infusions on adults with IgA nephropathy to see if it helps reduce protein in urine and improve kidney function compared to a placebo.

IgA Nephropathy>2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementInternal MedicineNephrology

Alopecia Areata: Ritlecitinib Study

We are investigating whether two doses of ritlecitinib can help people aged 12 and older with alopecia areata regrow their scalp hair. The study compares the effects of the medication to a placebo.

Alopecia Areata6-12 monthsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementPartially RemoteAllergologyDermatology

Severe Asthma: Verekitug (UPB-101) Study

We are studying the long-term safety and effects of verekitug in adults with severe asthma. This research aims to see how it helps manage asthma attacks and improve breathing.

Severe Asthma1-2 yearsEfficacy phase (II)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteAllergologyPulmonology

Choline Chloride for Injection in Intestinal Failure

We are studying the safety and effectiveness of Choline Chloride for Injection in adolescents and adults with intestinal failure. This trial compares the treatment to a placebo to see how well it supports patients receiving long-term parenteral nutrition.

Intestinal Failure1-2 yearsEfficacy phase (II)Confirmation phase (III)16-20 visitsPost-Trial Drug AccessStandard MedicinesGastroenterologyNephrology

Blood Cancer Treatment: CCS1477 Study

We are testing the safety and effects of the experimental drug CCS1477 in patients with advanced blood and bone marrow cancers. This study aims to see how well it works alone and in combination with other treatments.

Acute Myeloid Leukaemia (AML)Myelodysplastic Syndrome (MDS)Multiple Myeloma (MM)Safety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesHematologyOncology

Metastatic Colorectal Cancer: New Diagnostic Test for Treatment Guidance

We are studying a new test to help doctors determine the best third-line therapy for patients with metastatic colorectal cancer. The goal is to see if this test provides accurate and reliable information for treatment decisions.

Metastatic Colorectal Cancer>2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesInternal MedicineOncology

Hidradenitis Suppurativa: Tibulizumab Study

We are evaluating the effects of tibulizumab on skin lesions and quality of life for adults with hidradenitis suppurativa. The study also looks at the safety and tolerability of this treatment.

Hidradenitis Suppurativa6-12 monthsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesDermatology

Sickle Cell Disease: Tebapivat Study

We are investigating a new medication, tebapivat, to see if it helps improve anemia in people with sickle cell disease. The study will also look at its safety and effects on fatigue and pain.

Sickle Cell Disease3-6 monthsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteHematologyInternal Medicine

Atopic Dermatitis: Long-term Study of APG777

We are examining the long-term safety and effectiveness of APG777 in patients with moderate-to-severe atopic dermatitis who have already used this treatment. The goal is to see how well it works over time and if it remains safe.

Atopic DermatitisEfficacy phase (II)Post-Trial Drug AccessInvestigational MedicinesPartially RemoteAllergologyDermatology

Non-Small Cell Lung Cancer: BMS-986504 Treatment Study

We are evaluating a new medication for patients with advanced non-small cell lung cancer who have a specific genetic deletion. The study aims to understand how well it works and its safety compared to previous treatments.

Advanced or Metastatic Non-small Cell Lung CancerEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesOncologyPulmonology

Narcolepsy and Idiopathic Hypersomnia: ALKS 2680 Study

We are investigating the safety and tolerability of ALKS 2680 for people with narcolepsy and idiopathic hypersomnia. The study also looks at its effects on excessive daytime sleepiness and cataplexy.

Narcolepsy and Idiopathic Hypersomnia>2 yearsEfficacy phase (II)Confirmation phase (III)>20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteNeurology

ALS Treatment: EH-301 and N-Acetylcysteine with Riluzole

We are studying a new combination therapy for people with ALS to see if it can slow disease progression and improve muscle strength and quality of life. This trial compares the treatment to a placebo to evaluate its effectiveness.

Amyotrophic Lateral Sclerosis (ALS)1-2 yearsSafety phase (I)Efficacy phase (II)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesNeurology

Nucresiran for Transthyretin Amyloidosis with Cardiomyopathy

We are studying whether Nucresiran can help reduce serious heart-related events in patients with transthyretin amyloidosis. The trial compares its effects to a placebo to assess overall health improvements.

Transthyretin Amyloidosis with Cardiomyopathy>2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementCardiologyInternal Medicine